Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), executed a distribution services agreement with Cencora – formerly AmerisourceBergen -, a global pharmaceutical services company. This agreement marks another significant step forward in the company’s commercial launch strategy for Lymphir, its FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma. This new agreement expands Citius Oncology’s commercial distribution network. Cencora will serve as a wholesale distributor for Lymphir, providing specialty distribution services to facilitate product availability across its distribution network.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTOR:
- Citius Oncology files to sell $15M of common stock, warrants
- Citius Oncology Regains Nasdaq Compliance June 2025
- Citius Oncology Prepares for LYMPHIR™ Launch
- Citius Oncology expects commercial launch of Lymphir in second half of 2025
- Citius Oncology enters distribution services agreement with Cardinal Health